首页> 外文OA文献 >Stem cell transplantation of matched sibling donors compared with immunosuppressive therapy for acquired severe aplastic anaemia: a Cochrane systematic review.
【2h】

Stem cell transplantation of matched sibling donors compared with immunosuppressive therapy for acquired severe aplastic anaemia: a Cochrane systematic review.

机译:与获得性重型再生障碍性贫血的免疫抑制治疗相比,匹配的同胞供体的干细胞移植:Cochrane系统评价。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVES: Acquired severe aplastic anaemia is a rare and potentially fatal disease. The aim of this Cochrane review was to evaluate the effectiveness and adverse events of first-line allogeneic haematopoietic stem cell transplantation of human leucocyte antigen (HLA)-matched sibling donors compared with first-line immunosuppressive therapy. ududSETTING: Specialised stem cell transplantations units in primary care hospitals. ududPARTICIPANTS: We included 302 participants with newly diagnosed acquired severe aplastic anaemia. The age ranged from early childhood to young adulthood. We excluded studies on participants with secondary aplastic anaemia. ududINTERVENTIONS: We included allogeneic haematopoietic stem cell transplantation as the test intervention harvested from any source of matched sibling donor and serving as a first-line therapy. We included immunosuppressive therapy as comparator with either antithymocyte/antilymphocyte globulin or ciclosporin or a combination of the two. ududPRIMARY AND SECONDARY OUTCOME MEASURES PLANNED AND FINALLY MEASURED: The primary outcome was overall mortality. Secondary outcomes were treatment-related mortality, graft failure, graft-versus-host disease, no response to immunosuppressive therapy, relapse after initial successful treatment, secondary clonal disease or malignancies, health-related quality of life and performance scores. ududRESULTS: We identified three prospective non-randomised controlled trials with a study design that was consistent with the principle of 'Mendelian randomisation' in allocating patients to treatment groups. All studies had a high risk of bias due to the study design and were conducted more than 15 years. The pooled HR for overall mortality for the donor group versus the no donor group was 0.95 (95% CI 0.43 to 2.12, p=0.90). ududCONCLUSIONS: There are insufficient and biased data that do not allow any firm conclusions to be made about the comparative effectiveness of first-line allogeneic haematopoietic stem cell transplantation of HLA-matched sibling donors and first-line immunosuppressive therapy of patients with acquired severe aplastic anaemia.
机译:目的:获得性严重再生障碍性贫血是一种罕见且可能致命的疾病。这项Cochrane综述的目的是评估与一线免疫抑制疗法相比,与人白细胞抗原(HLA)匹配的同胞供体一线同种异体造血干细胞移植的有效性和不良事件。 ud udSETTING:基层医院的专门干细胞移植单位。 ud ud参与者:我们纳入了302名新诊断为获得性严重再生障碍性贫血的参与者。年龄从幼儿到成年。我们排除了继发再生障碍性贫血参与者的研究。 ud ud干预措施:我们将同种异体造血干细胞移植纳入了从任何匹配的同胞供体来源中收集的测试干预措施,并将其作为一线疗法。我们将免疫抑制疗法作为抗胸腺细胞/抗淋巴细胞球蛋白或环孢菌素或两者的组合的比较剂。 ud ud主要和最终测量的主要和次要指标:主要终点是总体死亡率。次要结果是与治疗有关的死亡率,移植失败,移植物抗宿主病,对免疫抑制疗法无反应,初次成功治疗后复发,继发性克隆疾病或恶性肿瘤,与健康有关的生活质量和表现评分。 ud ud结果:我们确定了三项前瞻性非随机对照试验,其研究设计与患者分配给治疗组时的“孟德尔随机化”原理一致。由于研究设计的原因,所有研究都有很高的偏见风险,并且进行了15年以上。供体组与无供体组的总死亡率的合并HR为0.95(95%CI为0.43至2.12,p = 0.90)。结论:目前尚无充分且有偏见的数据,无法就HLA匹配同胞供体一线同种异体造血干细胞移植和获得性肝癌患者的一线免疫抑制疗法的相对有效性做出任何确切结论严重的再生障碍性贫血。

著录项

  • 作者

    Peinemann F.; Labeit A.M.;

  • 作者单位
  • 年度 2014
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号